Tucker Asset Management LLC Sells 1,342 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Tucker Asset Management LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,598 shares of the biopharmaceutical company’s stock after selling 1,342 shares during the period. Tucker Asset Management LLC’s holdings in Gilead Sciences were worth $517,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the fourth quarter worth about $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC grew its position in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.6 %

Shares of NASDAQ:GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a market capitalization of $139.22 billion, a PE ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business has a fifty day moving average price of $105.48 and a two-hundred day moving average price of $94.81. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Bank of America raised their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Oppenheimer lifted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.